“We are driving the market to exome and genome testing with a goal of making multigene panels be a thing of the past” Katherine Stueland, CEO of GeneDx, tells Bloomberg Intelligence’s analyst Jonathan Palmer on this episode of the Vanguards of Health Care podcast. They discuss GeneDx’s 80% market share in exome sequencing, the evolution of the genetic testing market and why the company’s core mission is delivering clinically-actionable results in rare diseases.  

<p>“We are driving the market to exome and genome testing with a goal of making multigene panels be a thing of the past” Katherine Stueland, CEO of GeneDx, tells Bloomberg Intelligence’s analyst Jonathan Palmer on this episode of the Vanguards of Health Care podcast. They discuss GeneDx’s 80% market share in exome sequencing, the evolution of the genetic testing market and why the company’s core mission is delivering clinically-actionable results in rare diseases.  </p>

Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.

<p>Vanguards of Healthcare is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations.</p>

Vanguards of Healthcare by Bloomberg Intelligence

GeneDx Betting on the Future of Exome and Genome Testing

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/80a17b9a-8835-4811-a15f-b1560117336c/transcript